BDBM577683 US11478451, Example 087::US11478451, Example 088::US11478451, Example 089

SMILES Cc1c-2c(COCCn3c(C(O)=O)c(CCCOc4cccc5ccccc45)c4ccc(Cl)c-2c34)nn1C

InChI Key InChIKey=FQNIYAGBZSSXJR-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 577683   

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 1.20E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 13nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 9.00E+3nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 1.60E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 1.80E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent